Certara Enhances Biosimulation Capabilities with Acquisition of Applied BioMath

PRINCETON, N.J. – Certara, Inc. CERT, a global leader in biosimulation software and technology for drug discovery and development, has announced a strategic acquisition that promises to revolutionize the company's service offerings. The acquisition of Applied BioMath, a pioneering company in model-informed drug discovery and development, is set to expand Certara's biosimulation portfolio significantly. This move aims to bridge the gap between therapeutic research and development (R&D) and the efficient determination of optimal dosing for novel therapies.

Strategic Expansion in Biosimulation

Certara CERT, headquartered in Princeton, New Jersey, is renowned for its sophisticated software products and technology services, which serve a critical role across various stages of drug discovery and development. With the procurement of Applied BioMath, Certara underscores its commitment to enhancing its biosimulation solutions. The integration of the newly acquired company's expertise is expected to industrialize new capabilities, thereby providing clients with unprecedented support in the fast-paced and risky domain of therapeutic R&D.

Industrializing New Capabilities

The process of determining the optimal dosing for novel therapies is a complex one, fraught with uncertainties and high stakes. Applied BioMath's model-informed approaches equip Certara with tools to accelerate this process, while simultaneously reducing the risks associated with therapeutic development. The synergy between Certara's existing biosimulation portfolio and Applied BioMath's methodologies is poised to deliver comprehensive solutions that could potentially transform the landscape of drug development.

Implications for Stakeholders

For stakeholders of Certara CERT, this acquisition signifies a performance-driven future wherein the company is better equipped to address the challenges of drug development through cutting-edge biosimulation. The expanded capabilities promise to streamline workflows, optimize resource allocation, and enhance the predictability of therapeutic outcomes—factors that are essential for maintaining a competitive edge in the biopharmaceutical industry.

Certara, Acquisition, Biosimulation